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ABSTRACT 
 
Aims: To examine the effects of ascorbic acid (AA), dehydroascorbic acid (DHA) and methotrexate 
(MTX) combined treatments on (MDA-MB-231) breast cancer cell viability and intracellular reactive 
oxygen species (ROS).  
Study Design: In-vitro method. 
Place and Duration of Study: Biomedical Sciences Research Institute, University of Ulster, 
Coleraine, BT52 1SA, United Kingdom. September 2016-2017 
Methodology: Cytotoxicity tests were performed with MTX (0.01- 1000 µmol/l) alone or in 
combination with AA or DHA, for 72 h. Cell viability was measured by 3-4,5 dimethylthiazol-2,5 
diphenyl tetrazolium bromide (MTT) or Sulforhodamine B (SRB) assays. Intracellular ROS was 
measured by 2’,7’-dichlorofluroscein diacetate assay. 
Results: Treatments of MDA-MB231 cells with single agents, showed dose dependent response 
with 50% inhibition of cell viability (IC50) of 110.5-201.4 µmol/l (MTX), 2237-5703 µmol/l (AA) or 
2474 µmol/l (DHA). Combination studies showed clear synergisms for MTX (~10 µmol/l) and DHA 
or AA (1100 µmol/l) but weak or no interactions at other concentrations. Three days combination 
treatment of DHA showed decrease of ROS, which was reversed by MTX (>10 µmol/l).   
Conclusions: Co-treatment of methotrexate with AA or DHA showed synergism (C1<1.0) and 
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enhanced cytotoxicity of the anti-folate towards MDA-MB-231 breast cancer cells. Intracellular ROS 
decreased with AA and DHA treatment, which might be useful for reducing MTX-related oxidative 
stress. 
 
 
Keywords: Ascorbic acid; dehydroascorbic acid; methotrexate; breast cancer; MDA-MB-231 cells; 
Reactive oxygen species. 
 
1. INTRODUCTION  
 
Breast cancer is the most common cancer that 
affects women worldwide [1]. In the UK, 1 in 8 
women may develop breast cancer in their 
lifetime. In 2014, estimates show that 11,433 
people died from breast cancer in the UK alone 
[2]. Methotrexate (MTX) is an anti-folate drug 
developed in the late 1940s for the treatment of 
acute lymphocytic leukemia and other 
malignancies [3]. MTX cytotoxicity is linked with 
oxidative stress and increases of intracellular 
reactive oxygen species (ROS) [4]. MTX therapy 
also leads to a reduction in the levels of 
glutathione (GSH) in tissues [5], leading to 
changes in the redox state, which makes cells 
more susceptible towards ROS [4,6,7].  
 
Treatment of malignancies with MTX requires a 
high dose therapy, and is associated with side 
effects [2], due to the drug not differentiating 
between normal and cancerous cells [6]. Rapidly 
dividing cells are particularly susceptible to MTX 
side-effects [8], resulting in hepatotoxicity, 
myelosuppression, nephrotoxicity, and intestinal 
toxicity [2,9]. 
 
Supplementation using folic acid or folinic acid 
are well known strategies for dealing with MTX 
toxicity [10] but may increase the chances of 
relapse in patients with leukemia [2].  Antioxidant 
supplements were found to reduce MTX toxicity 
linked with high ROS [5,6,7,8]. There is 
longstanding interest in the potential anticancer 
effects of ascorbic acid (AA), which is a nutrient 
and a well-known antioxidant [11,12,13,14,15]. 
Vitamin C had anti-proliferative activity [13], and 
could enhance effects of doxorubicin, cisplatin 
and paclitaxel [14], mitoxantrone [15], and 
methotrexate [16,17]. Other studies however, 
suggested that AA might antagonize 
antineoplastic drugs leading to reductions in 
effectiveness [18]. Moreover, AA was noted as a 
pro-oxidant [19] and in that case is unlikely to 
reduce drug side effects. Aside from the studies 
cited above, the use of AA and dehydroascorbic 
acid (DHA) to reduce MTX toxicity has not been 
thoroughly studied. The aim of this investigation 
was to, examine the effects of AA, DHA and MTX 
combined treatments on MDA-MB-231 breast 
cancer cell cytotoxicity and intracellular reactive 
oxygen species (ROS).  
 
2. MATERIALS AND METHODS  
 
2.1 Cell Culture and Plating of Cells 
 
MDA-MB-231 breast cancer cells (American 
Type Culture Collection, UK) were cultured in 
Dulbecco Modified Eagle’s Medium (DMEM) 
(Gibco, UK) supplemented with 10% FBS 
(Invitrogen, UK), 1% Penicillin/Streptomycin 
(Penn strep) (Invitrogen, UK) and 1% non-
essential amino acid (Invitrogen, UK). Culture 
flasks and 96 well plates were incubated at 37˚C 
in an atmosphere of 5% CO2 (LEEC Research 
CO2 Incubator, LEEC Ltd., Nottingham, UK). 
MDA-MB-231 cells were recovered by 
trypsinization. The recovered cells were counted 
using NucleoCounter® (NC-3000, ChemoMetec, 
Denmark) according to the manufactures 
instructions. A master mix of cells was prepared 
to deliver 10,000 cells in a 50 µl suspension per 
well and these dispensed into microplates under 
sterile conditions (ThermoScientific, UK).  
 
2.2 Drug Treatment  
 
A stock solution of MTX (100 mmol/l) dissolved 
with dimethyl sulfoxide (DMSO) was diluted 10-
fold with DMEM and filter sterilized using 0.2 µm 
filters (Millex-HA sterile filter units; Merck 
Millipore Ltd, Co. Cork Ireland). The MTX 
solution in DMEM media was serially diluted at 
concentrations 0.01, 0.1, 1, 10, 100, 1000 µmol/l 
using DMEM. AA or DHA was first dissolved in 
DMEM media (2 - 20 mmol/l) and filter sterilized 
using 0.2 µm filters and serially diluted at 
concentration 0.1, 1, 10, 100, 1000, 10000 
µmol/l). Sterile solutions of drugs to be tested (50 
µl) were added to cells at the 2x-concentrations 
mentioned and incubated for 72 h at 37˚C. Cell 
viability was measured using MTT or 
sulforhodamine B (SRB) assays [20,21]. 
 
2.3 Combination Drugs Study 
 
The 50% inhibitor concentration for each agent 
(IC50) was determined and one half of the IC50 
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of AA and DHA found to be approximately 1100 
µmol/l (see below). Therefore, AA or DHA (1100 
µmol/l) was used for combination with varying 
concentration of MTX.  Cells were treated with 
MTX (0.1, 1.0, 10, 100, 1000 µmol/l final 
concentrations) and a fixed concentration of AA 
or DHA at 1100 µmol/l for 72 hours and MTT and 
SRB assays. Cell viability results were analysed 
by CompuSyn™ software [22,23] to determine, 
the IC50 alongside of the combination index (CI), 
where CI <1, CI =1 or CI >1 shows, synergism, 
additive responses or antagonism, respectively. 
A combination study of DHA and MTX was also 
performed for the determination of reactive 
oxygen species (ROS) using 2’, 7’- 
dichlorofluorescein diacetate (DCFH-DA) assay. 
 
2.4 MTT Assay and Sulforhodamine B 
Assays for Cell Viability 
 
The MTT assay was performed as described 
before [20] with modification. MTT (5mg per 100 
ml PBS) was filter sterilized (0.2 µM filter) before 
use.  Cells were washed three times with cold 
PBS (50 µl x3) leaving behind 50 µL of PBS in 
each well. MTT solution (20 µl) was added to 
each well and microplates were incubated at 
37˚C for 2 h. Formazan crystals formed were 
dissolved by treating with  100 µl acidified 
isopropanol (with 0.04M HCL) for 1 h. 
Absorbance was read at 570 nm using a 
microplate reader (VERSA Max Micro plate 
reader; Molecular Devices, USA).  
 
Sulforhodamine B (SRB) staining was carried out 
according to the method described in [21] with a 
few modifications. Cells were fixed with 100 µl of 
cold trichloroacetic acid (TCA 10% w/v) and 
incubated at 5°C for 30 minutes. Cells were 
washed four times with tap water, blot dried after 
each wash, and then stained with 100 µl of SRB 
dye (0.06% solution in 1% acetic acid) (Sigma-
Aldrich, UK) at room temperature for 30 minutes. 
Plates were de-stained by washing with 1% 
acetic (100 µl x3) acid and allowed to air dry. 
Trizma-base solution (10 mmol/l) was added to 
each well (200 µl) and placed on a shaker for 5 
min. Absorbance was read at 564 nm on a 
microplate reader. 
. 
2.5 DCFH-DA Assay 
 
Intracellular ROS was determined using DCFH-
DA assay [24]. DCFH- DA stock solution (20.5 
mmol/l) was made by adding 10 mg of DCFH-DA 
with 1 ml of DMSO (1 ml). To make DCFH-DA 
working solution, 10 ml of hank salt solution was 
added to 25 µl of DCFH-DA stock solution in a 
universal container and was filter sterilised. Cells 
were plated to deliver 10,000 cells/well in 96 well 
black polystyrene plates with 50 µL media per 
well and incubated overnight at 37°C to allow for 
the adherence of cells.  
 
For the 60 min study cells were washed once 
with cold 200 µl of hank salt solution, which was 
then pipetted out. DCFH-DA working solution (50 
µl) was added to cells and incubated for 45 min 
at 37˚C. Cells were then rinsed once with 200 µl 
of culture media DMEM, Drug treatment was 
performed by treating cells with AA or DHA as 
described above (Section 2.2.) with media as 
control and incubated for 60 min at 37°C. 
Fluorescence was read at 485 nm excitation and 
520 nm emission wavelengths on a microplate 
reader (FLUOstar Omega, BMG Labtech, 
Germany). A 72-h treatment study with DHA and 
MTX was performed as described above except 
drug treatment was for 72 h. Experiments were 
performed on at least two separate occasions 
with each drug treatment concentration repeated 
at least 12-24 times. 
 
2.6 Statistical Analysis 
 
One-way ANOVA tests were performed using 
SPSS software version 23 to identify significant 
differences between the means of treatments 
groups, statistical significant differences were 
considered to be P value <0.05. Results are 
expressed as mean ± standard error.  
 
3. RESULTS  
 
3.1 Single Drug Tests, MTT Assay for 
MDA-MB-231 Breast Cancer 
 
Single drug tests were performed using MTX, AA 
and DHA on MDA-MB-231 breast cancer cells for 
72 h and then cell viability was assessed by the 
MTT assay (Fig. 1). There was dose-dependent 
decrease in cell viability.  By contrast, AA and 
DHA were found to be non-cytotoxic at the 
concentrations examined (Fig. 1). The 
concentrations of each agent giving 50% 
inhibition of cell viability (IC50) were estimated 
from CompuSyn
TM   
software and are shown in 
Table 1 (MTT assay). When using the MTT 
assay, there was no cytotoxicity effect for DHA 
even at concentrations of 10 mmol/l (data not 
shown).  
 
 
 
 
 
Dosunmu and Owusu-Apenten; JALSI, 14(2): xxx-xxx, 2017; Article no.JALSI.37185 
 
 
 
4 
 
Table 1. Dose-response parameters 
determined by CompuSyn™ for MTT Assay 
 
MTT assay IC50 m r CI 
MTX 201.4 0.64 0.71 N/A 
AA 5703 3.97 1 N/A 
DHA Infinite 0 - N/A 
AA+MTX Combo N/A N/A N/A 0.43 
DHA+MTX Combo  N/A N/A N/A - 
*IC50 = median dose (µmol/l), m = response slope, 
 r = regression coefficient, CI = combination index. CI 
corresponds to treatment 3 (MTX 10 µmol/l + 1100 µmol/l 
AA or DHA). 
 
3.2 Single Drug Tests, Sulforhodamine 
Assay for MDA-MB-231 Breast  
 
Single drug tests were performed using MTX, AA 
and DHA on MDA-MB-231 breast cancer cells for 
72 h and with cell viability assessed by the 
sulforhodamine assay (Fig. 2). For MTX, a 
significant decrease in cell viability of 39% and 
54% were seen for treatment 4 and 5, 
respectively compared to the control (treatment 
1). The highest concentrations of AA and DHA 
tested produced a decrease in cell viability of 
14% for AA and 16% for DHA. Table 2 shows the 
IC50 values for MTX, AA and DHA respectively. 
 
3.3 Combination Treatment of MDA-MB-
231 Cells with MTX and AA or DHA 
 
The combination index (CI) determined by 
CompuSyn ranged from 0.43- 251 when cells 
viability was assayed using MTT assay while, CI 
range 0.46-0.91 with the SRB assay (Table 2). 
The CI values correspond to treatments with 10 
µmol/l of MTX + 1100 µmol/l AA (as seen in Fig. 
1 & Fig. 2, treatment 3).  For the MTX and DHA 
combination treatment monitored with the MTT 
assay no toxicity effect was seen in DHA, as a 
result no CI value could be calculated. A CI value 
of 0.91 was obtained for MTX and DHA 
combination treatment for SRB assay (Table 2), 
which is the middle dose treatment that contains 
10 µmol/l of MTX + 1100 µmol/l DHA showing 
synergism (also seen in Fig. 2, treatment 3). 
 
3.4 CompuSyn Predictions for CI over 
Wider Concentration Ranges 
 
For all combination studies, CompuSyn analysis 
predicted large values for CI when at low 
concentrations of MTX (e.g. C1 = 0.41- 5000 and 
CI = 0.91). The significance of such large 
predicted CI value is not certain. 
Table 2. Dose-response parameters 
determined by CompuSyn™ for SRB assay 
 
SRB assay IC50 m r CI 
MTX 110.5 0.89 0.88 N/A 
AA 2237 0.86 0.91 N/A 
DHA 2474 0.70 0.96 N/A 
AA+MTX Combo N/A N/A N/A 0.46 
DHA+MTX Combo N/A N/A N/A 0.91 
*IC50 = median dose (µmol/l), m = response slope, r = 
regression coefficient, CI = combination index. CI 
corresponds to treatment 3 (MTX 10 µmol/l + 1100 µmol/l 
AA or DHA). 
 
3.5 Drug Effects on Intracellular ROS in 
MDA-MB-231 Cells  
 
One-hour treatment with 1-1000 µmol/l of AA or 
DHA produced small changes (+/- 10%) changes 
in intracellular ROS with no consistent pattern 
(data not shown).  By comparison treatment with 
DHA for 72 hours produced a 50% decrease of 
ROS compared with media only control (Fig. 3). 
For comparison, treatment with MTX (0.1-1000 
µM) plus a fixed DHA (1100 µmol/l) showed no 
apparent tendency to increase the ROS above 
the value for the control. Assuming that the ROS 
changes derive only from viable cells, the 
preceding results were also adjusted to take 
account of percentage changes in cell viability 
(Fig. 3). The intracellular ROS data for viable 
cells showed that MTX co-treatments at >10 
µmol/l produced rising levels of oxidative stress 
(Fig. 3, Shaded bars).  
 
4. DISCUSSION 
 
Therapeutic use of MTX for breast cancer 
treatment could be improved if the toxic side 
effects due to ROS were eradicated. Many 
studies have reported using various antioxidants 
to decrease MTX toxicity by lowering ROS [5,7,8, 
25,26,27]. Other studies reported the anti-cancer 
ability of AA, with concentration of 0.25-1 mmol/l 
being able to cause toxicity in cancer cells [11, 
12,28-30.] However, AA at lower concentration 
was shown to act as a protector for cells.  which 
might explain some of the conflicting results 
reported [14,26]. AA was also reported to be 
more toxic to cancer cells compared with normal 
cells, though the reasons behind this selectivity is 
not clear [28-30]. Studies have shown AA can 
lower the side effects caused by neoplastic drugs 
by enhancing their cytotoxicity, resulting in lower 
dosage of these drugs being used for cancer 
treatment [14-17].  
Dosunmu and Owusu
Fig. 1. Effect of methotrexate (MTX) treatment 
Ascorbic acid (AA; Top) or dehydroascorbic acid (DHA; lower panel) with cell viability 
The x-axis shows treatments (1-5) with AA (0.1, 1.0, 10, 100, 1000 µmol/l), MTX (0.01, 0.1. 1.0, 10, 1
and combinations (0.1, 1.0. 10, 100, 1000 µmol/l MTX) +1100 µmol/l AA or DHA. Bars with different letters (A
show significant differences (p value <0.05). Results are expressed as mean ± standard error. Experiment were 
repeated on two different occasions n =12
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-24 of pooled data. Final DMSO concentration = 0%, 0.001%, 0.01%, 
0.1% and 1% for treatments 1-5. 
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Dosunmu and Owusu
Fig. 2. Effect of methotrexate (MTX) treatment with MDA
Ascorbic acid (AA; Top) or dehydroascorbic acid (DHA; lower panel) with cell viability 
determined by 
The x-axis shows treatments (1-5) with AA (0.1, 1.
and combinations (0.1, 1.0. 10, 100, 1000 µmol/l MTX) +1100 µmol/l AA or DHA in all cases. Bars with different 
letters (A-E) show statistical significant differences (p value <0.05). Results a
error. Experiment were repeated on two different occasions n =12
= 0%, 0.001%, 0.01%, 0.1% and 1% for treatments 1
 
 
Fig. 3. Effect of dehydroascorbic acid (DHA) and 
on MDA
Cells were treated with MTX (0.1, 1.0. 10, 100, 1000 µmol/l) + DHA at a fixed concentration of 1100 µmol/l.  
Negative control = cell treated with no drug (0), Positive control 
shows mean ± standard error (left axis). % Cell Viability (right axis) is continuous 
adjusted for viable cells. Experiments 
DMSO concentration =  0.001%, 0.01%, 0.1% and 1% for MTX treatments 0.1
 
In this study, the cytotoxicity of MTX, AA and 
DHA were tested for each compound using 
MDA-MB-231 cells. The cytotoxicity of MTX was 
demonstrated but IC50 values that were found 
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-MB-231 cells in combination with 
sulforhodamine B assay. 
0, 10, 100, 1000 µmol/l), MTX (0.01, 0.1. 1.0, 10, 100 µmol/l), 
re expressed as mean ± standard 
-24 of pooled data. Final DMSO concentration 
-5. 
 
methotrexate (MTX) combination treatments 
-MB-231 intracellular ROS cells 
= cell treated with DHA (1100 µmol/l). ROS data 
line. Shaded bars = ROS 
were repeated on two different occasions n = 12-24 of pooled
-1000 µmol/l.
that proved to be higher than that of the only 
study (to our knowledge) that p
analyses under very similar conditions.  
Owusu-Apenten found the IC50 of MTX was 3
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µmol/l after 72 h of treatment using the MTT 
assay in MDA-MB-231 cells, which is significantly 
lower than the IC50 of 201.4 µmol/l obtained in 
this study [31]. Other studies that reported the 
IC50 of MTX used drug treatments at a shorter 
time or/and with different cell lines. The IC50 for 
both AA and DHA were found to be similar using 
the SRB assay. To our knowledge, no previous 
study reported an IC50 for AA and DHA in MDA-
MB-231 cells. Frömberg et al. reported the IC50 
of AA and DHA in other cells lines, as 1.7 to > 60 
mM (AA) or 12.7- 14.9 mM (DHA) and concluded 
that AA demonstrated a higher therapeutic effect 
over DHA in the cell lines [13]. 
 
Investigating both AA and DHA combination with 
MTX was intended to shed light on the effect of 
two different AA forms. AA is an antioxidant and 
nutrient supplement. DHA is the oxidised form of 
AA and has antioxidant capacity [18]. Although 
the level of AA found in the human serum is 
relatively high, intracellular transportation is 
thought to limited to only a few tissues. In 
contrast, DHA enters cells readily by the glucose 
transporter (GLUT1). Intracellular DHA becomes 
reduced and accumulates in the cell, leading to 
increased levels of intracellular AA. High 
concentrations of AA in cells works with 
endogenous GSH to reduce the effects of ROS 
[18].  Past research showed that AA may behave 
as a pro-oxidant at higher concentration by 
producing ROS, which is a possible reason for its 
anti-cancer ability [12,19]. It is noteworthy that for 
normal tissue, AA is taken up by sodium-
dependent vitamin C transporters (SVCT) [32]. 
The similar cell viability responses observed with 
AA and DHA (Fig. 1 &2) suggests that AA was 
oxidized extracellularly to DHA before uptake, as 
was demonstrated for leukaemia (K562) and 
lymphoma (RL) cells [18] and other cell lines 
[33]. However, the distribution of SVCT in breast 
cancer cell lines can neither be confirmed nor 
dismissed at present; therefor it is not certain 
whether efficient uptake of vitamin C by MDA-
MB-231 cells is or is not possible. 
 
According to current results, there were 
synergistic interactions between AA and MTX 
and also DHA and MTX. The synergistic effects 
were observed whether cytotoxicity was 
monitored by the MTT assay or SRB assay. To 
our knowledge, this is the first study to analyse 
the cytotoxicity of MTX, AA and DHA using both 
MTT and SRB assays. IC50 values obtained 
using the MTT assay were approximately double 
the IC50 values obtained for the SRB assay. The 
assays measure different indices for cells 
viability. The MTT assay measures mitochondrial 
activity while SRB assay measures cell protein. 
The former assay is influenced by acidic pH and 
reducing agents such as AA [20].  
 
Synergism was most apparent at treatment 
concentrations “straddling” the IC50 value for 
MTX (treatments 3-4, Figs. 1 & 2).  These 
findings agree with past reports [14,15,16]. 
Kurbacher et al reported that low levels (1 
µmole/l) of AA had a synergistic or additive 
response in combination with other neoplastic 
drugs in MDA-MB-231 and MCF-7 cells [14]. The 
concentrations of AA used were lower in 
comparison to the doses in this study. A recent 
study by Wu et al also reported a synergistic 
effect of non-toxic doses of AA combined with 
MTX and attributed such effects to increases of 
intracellular hydrogen peroxide and activation of 
apoptosis pathways [17]. Analysis of interactions 
based on values for CI requires a knowledge of 
the toxic doses for both agents under 
investigation and for this reason we examined 
AA and DHA over a wide concentration range. 
 
Intracellular ROS levels were largely unchanged 
(+/-10% control values) after an hour treatment 
with AA or DHA in MDA-MB-231 cells. By 
comparison, 72 hr treatment with DHA showed 
50% reduction in intracellular ROS, and the 
reduction was retained after addition of MTX 
(0.1-1000 µM). However, others reported that 
low concentrations of AA could increase ROS 
when combined with low doses of MTX in MDA-
MB-231 cells [17]. When in Fig 3, the intracellular 
ROS values are adjusted for viable cells it 
became evident that MTX increases oxidative 
stress at concentrations of >10 µM. Past 
research suggests that drug-induced ROS arise 
from a variety of processes affecting 
mitochondrial morphology and function [27,35], 
drug biotransformations, or autoxidation. 
Moreover, DCFH-DA intracellular probe shows 
mitochondrial and cytoplasmic changes to ROS 
[34]. Interestingly, recent research using 
astrocytes showed that ROS increases could 
arise from exposure to 1-5% DMSO due to 
changes of mitochondrial integrity [35].    
 
5. CONCLUSION 
 
Ascorbic acid and DHA were found to be 
cytotoxic towards MDA-MB-231 cells. 
Combination treatment of AA or DHA with MTX 
resulted in synergistic responses indicating 
improved effectiveness of the anti-folate drug. 
Analysis of intracellular ROS showed that AA or 
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DHA co-treatment could maintain low levels of 
oxidative stress. Further research is required to 
study different combinations of AA and MTX for 
treatment of breast cancer. 
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